Table IV.

SIRs based on observed rates from OBSERVE-5 and expected rates from MarketScan^*

MarketScan Comparator Group, SIR (95% CI)	Malignancy Excluding NMSC†	Lymphoma†	NMSC†	Infectious Event Requiring Hospitalization‡
Patients receiving nonbiologic systemic therapies	0.78 (0.59, 1.00)	0.26 (0.03, 0.95)	0.54 (0.42, 0.69)	0.34 (0.26, 0.43)
Patients receiving etanercept	0.89 (0.68, 1.15)	0.50 (0.06, 1.80)	0.58 (0.45, 0.74)	0.51 (0.39, 0.66)
Patients receiving phototherapy	0.74 (0.57, 0.96)	0.14 (0.02, 0.52)	0.54 (0.42, 0.69)	0.41 (0.32, 0.53)
Patients receiving other biologic therapies	0.97 (0.74, 1.25)	0.36 (0.04, 1.29)	0.46 (0.36, 0.58)	0.29 (0.22, 0.37)
Patients receiving methotrexate	0.78 (0.60, 1.00)	0.28 (0.03, 1.00)	0.55 (0.43, 0.70)	0.36 (0.27, 0.46)
Patients with psoriasis	0.81 (0.61, 1.04)	0.28 (0.03, 1.02)	0.62 (0.48, 0.79)	NA
General MarketScan population§	0.95 (0.72, 1.22)	0.46 (0.06, 1.67)	0.95 (0.73, 1.20)	NA

^*Incidence rates from MarketScan were age- and sex-standardized to the OBSERVE-5 population.

^†Analysis based on patient-years of observation.

^‡Analysis based on patient-years of exposure.

^§The general MarketScan population comprised all insured individuals who met the eligibility criteria.

SIRs, standardized incidence ratios; CI, confidence interval; NMSC, nonmelanoma skin cancer; NA, not applicable.